Home / Market News / $ARGX
benzinga Corporate Catalyst Impact 85/100 ● negative

Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis

Oct 8, 2026, 12:13 PM UTC · Primary ticker $ARGX

Argenx announced mixed clinical results, discontinuing a Phase 3 study for Sjögren's disease due to futility while reporting positive Phase 2 data for celiac disease. The discontinuation of the late-stage trial is a significant setback for the company's pipeline, leading to a sharp decline in its stock price.

Argenx delivered a mixed bag of clinical updates, with the headline news being the discontinuation of its Phase 3 UNITY trial for subcutaneous efgartigimod in Sjögren's disease. An independent data monitoring committee recommended stopping the study for futility, indicating the treatment was unlikely to meet its primary endpoint. This is a significant blow to Argenx's pipeline and growth prospects for efgartigimod beyond its approved indications, leading to a substantial premarket stock drop. Conversely, the company reported positive Phase 2 results for FB102 in celiac disease, offering a glimmer of hope for another pipeline candidate. However, the negative news regarding the Phase 3 failure overshadowed the positive Phase 2 data, highlighting the market's focus on late-stage clinical success. Traders should note the immediate negative impact on ARGX shares, with long-term implications depending on the success of other pipeline assets and the company's ability to pivot from this setback.

$ARGX negative Phase 3 study halted due to futility
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.